GSK to acquire BELLUS for £1.6 billion
A novel P2X3 antagonist is set to advance GSK's respiratory pipeline as part of its planned £1.6 billion acquisition of BELLUS Health.
List view / Grid view
A novel P2X3 antagonist is set to advance GSK's respiratory pipeline as part of its planned £1.6 billion acquisition of BELLUS Health.
The FDA has heard from professional groups, including the American Academy of Paediatrics about the use of opioid cough suppressants for children...
14 June 2016 | By Victoria White, Digital Content Producer
If approved, AF-219 would be the first new cough drug in 50 years and offer hope to the millions of people living with chronic cough...